Inhibiting Tim-3 results in accelerated lethality while increasing gal-9 expression results in decreased lethality. (A) B6 mice were lethally irradiated and infused with 107 BALB/c NTCD BM and 15 × 106 BALB/c splenocytes. Survival plot of IgG control (closed circle) versus Tim-3-Ig treatment (open circle) is shown (P = .012, n = 21-24/group). (B) B6 mice were lethally irradiated and infused with 107 BALB/c NTCD BM and 1 × 106 BALB/c or 1 × 106 Tim-3−/−–purified T cells. Survival plot of BALB/c (closed circle) versus Tim-3−/− (open circle) donor is shown (P = .083, n = 16/group). (C) B6 mice were lethally irradiated and infused with 107 BALB/c NTCD BM and 1 × 106 BALB/c or 1 × 106 Tim-3−/−–purified T cells. Mice were analyzed for clinical scores (n = 8/group). (D) BALB/c or gal-9 Tg mice were lethally irradiated and given 107 B6 NTCD BM and 2 × 106 B6-purified T cells. Survival plot of BALB/c versus gal-9 Tg recipients is shown (P < .01, n = 24/group). (E) gal-9 Tg mice were lethally irradiated and given 107 BALB/c NTCD BM and 3 × 106 BALB/c or 3 × 106 Tim-3−/−–purified T cells. Survival plot of BALB/c versus Tim-3−/− donors is shown (P = .217, n = 12/group).
